ZURICH (Reuters) - Novartis has secured the U.S. Food and Drug Administration’s Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.
Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a form of the disease for which there are no targeted therapies now, the Basel-based company said on Friday.
(This story fixes typographical error in first paragraph)
Reporting by John Miller; Editing by Michael Shields and David Goodman
Our Standards: The Thomson Reuters Trust Principles.